{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:21:23Z","timestamp":1791825683210,"version":"4.3.4"},"reference-count":62,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.idc.2020.04.003","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T05:32:52Z","timestamp":1601443972000},"page":"849-861","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Bacteremia due to Methicillin-Resistant Staphylococcus aureus"],"prefix":"10.1016","volume":"34","author":[{"given":"Marisa","family":"Holubar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Alegria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stan","family":"Deresinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.idc.2020.04.003_bib1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/AAC.01653-13","article-title":"Are vancomycin trough concentrations adequate for optimal dosing?","volume":"58","author":"Neely","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.idc.2020.04.003_bib2","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/cid\/ciz051","article-title":"Vancomycinarea under the curve and acute kidney injury: a meta-analysis","volume":"69","author":"Aljefri","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2020.04.003_bib3","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/cid\/ciz460","article-title":"The Emperor's new clothes: prospective observational evaluation of the association between initial vancomycin exposure and failure rates among adult hospitalized patients with MRSAbloodstream infections (PROVIDE)","volume":"70","author":"Lodise","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2020.04.003_bib4","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11534440-000000000-00000","article-title":"New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin","volume":"70","author":"Zhanel","year":"2010","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.idc.2020.04.003_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2146\/ajhp110572","article-title":"Oritavancin: an investigational lipoglycopeptide antibiotic","volume":"70","author":"Karaoui","year":"2013","journal-title":"Am J Health SystPharm"},{"key":"10.1016\/j.idc.2020.04.003_bib6","unstructured":"Rappo U, Gonzalez P, Akinapelli K, et\u00a0al. Outcomes in patients with Staphylococcus aureus bacteraemia treated with dalbavancin in clinical trials. Paper presented at: European Congress of Clinical Microbiology & Infectious Diseases. Vienna, Austria, April 22 - 25, 2017, 2017."},{"issue":"3","key":"10.1016\/j.idc.2020.04.003_bib7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40121-017-0162-1","article-title":"Telavancin in the treatment of concurrent staphylococcus aureus bacteremia: a retrospective analysis of ATLAS and ATTAIN studies","volume":"6","author":"Wilson","year":"2017","journal-title":"Infect Dis Ther"},{"issue":"1","key":"10.1016\/j.idc.2020.04.003_bib8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1128\/AAC.00617-15","article-title":"Case-control study of Telavancin as an alternative treatment for gram-positive bloodstream infections in patients with cancer","volume":"60","author":"Chaftari","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2020.04.003_bib9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/1471-2334-14-289","article-title":"A\u00a0randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study","volume":"14","author":"Stryjewski","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2020.04.003_bib10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/00365548.2014.995696","article-title":"Telavancin for refractory methicillin-resistant Staphylococcus aureus bacteremia and infective endocarditis","volume":"47","author":"Ruggero","year":"2015","journal-title":"Infect Dis"},{"issue":"15","key":"10.1016\/j.idc.2020.04.003_bib11","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.idc.2020.04.003_bib12","first-page":"568","article-title":"Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant Staphylococcus aureus persistent bacteraemia treated with daptomycin","volume":"69","author":"Gasch","year":"2014","journal-title":"J\u00a0AntimicrobChemother"},{"issue":"2","key":"10.1016\/j.idc.2020.04.003_bib13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/phar.2070","article-title":"Association of higher daptomycin dose (7\u00a0mg\/kg or Greater) with improved survival in patients with methicillin-resistant staphylococcus aureus bacteremia","volume":"38","author":"Timbrook","year":"2018","journal-title":"Pharmacotherapy"},{"issue":"10","key":"10.1016\/j.idc.2020.04.003_bib14","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11908-014-0429-6","article-title":"High-dose daptomycin therapy for staphylococcal endocarditis and when to apply it","volume":"16","author":"Smith","year":"2014","journal-title":"Curr Infect Dis Rep"},{"issue":"10","key":"10.1016\/j.idc.2020.04.003_bib15","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.1128\/AAC.00227-16","article-title":"Daptomycinimproves outcomes regardless of Vancomycin MIC in a propensity-matched analysis of methicillin-resistant Staphylococcus aureusbloodstream infections","volume":"60","author":"Claeys","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2020.04.003_bib16","first-page":"16","article-title":"Comparative effectiveness of vancomycin versus daptomycin for MRSAbacteremia with vancomycinMIC\u00a0>1\u00a0mg\/L: a multicenter evaluation","volume":"38","author":"Moise","year":"2016","journal-title":"ClinTher"},{"issue":"3","key":"10.1016\/j.idc.2020.04.003_bib17","first-page":"797","article-title":"Ceftarolinefosamil salvage therapy: an option for reduced-vancomycin-susceptible MRSAbacteraemia","volume":"70","author":"Espedido","year":"2015","journal-title":"J\u00a0AntimicrobChemother"},{"issue":"1","key":"10.1016\/j.idc.2020.04.003_bib18","first-page":"39","article-title":"CeftarolineFosamil for the treatment of staphylococcus aureus bacteremia secondary to acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia","volume":"23","author":"Vazquez","year":"2015","journal-title":"Infect Dis ClinPract"},{"issue":"5","key":"10.1016\/j.idc.2020.04.003_bib19","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1128\/AAC.02371-13","article-title":"Large retrospective evaluation of the effectiveness and safety of ceftarolinefosamil therapy","volume":"58","author":"Casapao","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.idc.2020.04.003_bib20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ijantimicag.2014.07.024","article-title":"Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureusbacteraemia with elevated vancomycin minimum inhibitory concentrations","volume":"44","author":"Paladino","year":"2014","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.idc.2020.04.003_bib21","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ijantimicag.2013.07.005","article-title":"Ceftaroline for meticillin-resistant Staphylococcus aureusbacteraemia: case series and review of the literature","volume":"42","author":"Polenakovik","year":"2013","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.idc.2020.04.003_bib22","first-page":"1267","article-title":"Methicillin-resistant Staphylococcus aureusbacteraemia and endocarditis treated with ceftaroline salvage therapy","volume":"67","author":"Ho","year":"2012","journal-title":"J\u00a0AntimicrobChemother"},{"issue":"8","key":"10.1016\/j.idc.2020.04.003_bib23","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/cid\/civ501","article-title":"Tedizolid: the first once-daily oxazolidinone class antibiotic","volume":"61","author":"Burdette","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2020.04.003_bib24","first-page":"923","article-title":"Linezolid versus vancomycin for Staphylococcus aureusbacteraemia: pooled analysis of randomized studies","volume":"56","author":"Shorr","year":"2005","journal-title":"J\u00a0AntimicrobChemother"},{"issue":"2","key":"10.1016\/j.idc.2020.04.003_bib25","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1128\/AAC.03688-14","article-title":"Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections","volume":"59","author":"Shorr","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2020.04.003_bib26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1086\/595686","article-title":"Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study","volume":"48","author":"Wilcox","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2020.04.003_bib27","first-page":"505","article-title":"Efficacy of linezolid-based salvage therapy compared with glycopeptide-based therapy in patients with persistent methicillin-resistant Staphylococcus aureus bacteremia","volume":"65","author":"Park","year":"2012","journal-title":"J\u00a0Infect"},{"issue":"3","key":"10.1016\/j.idc.2020.04.003_bib28","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/cid\/ciy916","article-title":"Early oral switch to linezolid for low-risk patients with Staphylococcus aureus bloodstream infections: a propensity-matched cohort study","volume":"69","author":"Willekens","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2020.04.003_bib29","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.diagmicrobio.2012.12.004","article-title":"Tigecycline: an update","volume":"75","author":"Stein","year":"2013","journal-title":"DiagnMicrobiol Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2020.04.003_bib30","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1086\/648720","article-title":"Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials","volume":"50","author":"Gardiner","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"Suppl1","key":"10.1016\/j.idc.2020.04.003_bib31","first-page":"i17","article-title":"Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study","volume":"62","author":"Florescu","year":"2008","journal-title":"J\u00a0AntimicrobChemother"},{"issue":"4","key":"10.1016\/j.idc.2020.04.003_bib32","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40262-019-00843-4","article-title":"Omadacycline: a review of the clinical pharmacokinetics and pharmacodynamics","volume":"59","author":"Rodvold","year":"2020","journal-title":"ClinPharmacokinet"},{"key":"10.1016\/j.idc.2020.04.003_bib33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jgar.2019.02.017","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017","volume":"19","author":"Huband","year":"2019","journal-title":"J\u00a0Glob Antimicrob Resist"},{"issue":"11","key":"10.1016\/j.idc.2020.04.003_bib34","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1128\/AAC.01288-13","article-title":"Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens","volume":"57","author":"Sutcliffe","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2020.04.003_bib35","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1128\/AAC.01204-13","article-title":"Beta-Lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone","volume":"58","author":"Dilworth","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.idc.2020.04.003_bib36","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/phar.2034","article-title":"Early administration of adjuvant beta-lactam therapy in combination with vancomycin among patients with methicillin-resistant Staphylococcus aureusbloodstream infection: a retrospective, multicenter analysis","volume":"37","author":"Casapao","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.idc.2020.04.003_bib37","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02211-18","article-title":"Adjuvant beta-lactam therapy combined with vancomycin for methicillin-resistant staphylococcus aureus bacteremia: does beta-lactam class matter?","volume":"63","author":"Dilworth","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2020.04.003_bib38","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01554-17","article-title":"Outcomes of Vancomycin plus a beta-Lactam versus Vancomycinonly for treatment of methicillin-resistant Staphylococcus aureusbacteremia","volume":"62","author":"Truong","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.idc.2020.04.003_bib39","doi-asserted-by":"crossref","first-page":"ofz079","DOI":"10.1093\/ofid\/ofz079","article-title":"The impact of concomitant empiric Cefepime on patient outcomes of methicillin-resistant staphylococcus aureus bloodstream infections treated with vancomycin","volume":"6","author":"Zasowski","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.idc.2020.04.003_bib40","article-title":"Adjunctive ceftaroline in combination with daptomycin or vancomycin for complicated methicillin-resistant Staphylococcus aureus bacteremia after monotherapy failure","volume":"6","author":"Hornak","year":"2019","journal-title":"TherAdv Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2020.04.003_bib41","first-page":"212","article-title":"Combination therapy with vancomycin and ceftaroline for refractory methicillin-resistant staphylococcus aureus bacteremia: a case series","volume":"39","author":"Gritsenko","year":"2017","journal-title":"ClinTher"},{"issue":"2","key":"10.1016\/j.idc.2020.04.003_bib42","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/cid\/civ808","article-title":"Combination of Vancomycin and beta-Lactam therapy for methicillin-resistant staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial","volume":"62","author":"Davis","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2020.04.003_bib43","unstructured":"Davis JS, Lye D, Nelson J. Combination antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia: the CAMERA2 randomised controlled trial Paper presented at: 29th European Congress of Clinical Microbiology & Infectious Diseases. Netherlands, 2019."},{"issue":"8","key":"10.1016\/j.idc.2020.04.003_bib44","doi-asserted-by":"crossref","first-page":"734","DOI":"10.4161\/viru.26909","article-title":"Vancomycinmonotherapy vs. combination therapy for the treatment of persistent methicillin-resistant Staphylococcus aureus bacteremia","volume":"4","author":"Seah","year":"2013","journal-title":"Virulence"},{"issue":"3","key":"10.1016\/j.idc.2020.04.003_bib45","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1086\/600295","article-title":"Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem","volume":"49","author":"Jang","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"10121","key":"10.1016\/j.idc.2020.04.003_bib46","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0140-6736(17)32456-X","article-title":"Adjunctive rifampicin for Staphylococcus aureusbacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Thwaites","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.idc.2020.04.003_bib47","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1128\/AAC.02192-12","article-title":"Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant beta-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment","volume":"57","author":"Moise","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idc.2020.04.003_bib48","first-page":"1936","article-title":"Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience","volume":"31","author":"Sakoulas","year":"2009","journal-title":"ClinTher"},{"issue":"10","key":"10.1016\/j.idc.2020.04.003_bib49","first-page":"1303","article-title":"Daptomycin in combination with other antibiotics for the treatment of complicated methicillin-resistant Staphylococcus aureus bacteremia","volume":"36","author":"Dhand","year":"2014","journal-title":"ClinTher"},{"key":"10.1016\/j.idc.2020.04.003_bib50","article-title":"Daptomycin plus beta-lactam combination therapy for methicillin-resistant Staphylococcus aureus bloodstream infections: a retrospective, comparative cohort study","author":"Jorgensen","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2020.04.003_bib51","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02483-18","article-title":"Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant staphylococcus aureus bacteremia","volume":"63","author":"Geriak","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.idc.2020.04.003_bib52","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00900-19","article-title":"Is daptomycin plus ceftaroline associated with better clinical outcomes than standard of care monotherapy for staphylococcus aureus bacteremia?","volume":"63","author":"Kalil","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.idc.2020.04.003_bib53","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1128\/AAC.01185-12","volume":"56","author":"Steed","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2020.04.003_bib54","unstructured":"ZasowskiEJ, Claeys KC, Roberts KD, et\u00a0al. Retrospective Evaluation of Daptomycin (DAP) plus Ceftarolinefosamil (CPT) versus DAP plus Sulfamethoxazole\/Trimethoprim (SMX\/TMP) for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections (BSI). Paper presented at: 25th European Congress of Clinical Microbiology and Infectious Diseases. Cogenhagen, Denmark, 2015."},{"issue":"2","key":"10.1016\/j.idc.2020.04.003_bib55","doi-asserted-by":"crossref","first-page":"ofu046","DOI":"10.1093\/ofid\/ofu046","article-title":"Ceftaroline in combination with trimethoprim-sulfamethoxazole for salvage therapy of methicillin-resistant staphylococcus aureus bacteremia and endocarditis","volume":"1","author":"Fabre","year":"2014","journal-title":"Open Forum Infect Dis"},{"issue":"suppl_1","key":"10.1016\/j.idc.2020.04.003_bib56","doi-asserted-by":"crossref","first-page":"S760","DOI":"10.1093\/ofid\/ofy229.2177","article-title":"LB3.Daptomycinplus fosfomycin vs. daptomycinmonotherapy for methicillin-resistant staphylococcus aureus bacteremia: a multicenter, randomized, clinical trial","volume":"5","author":"Pujol","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2020.04.003_bib57","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/cid\/ciu580","article-title":"Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial","volume":"59","author":"del Rio","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2020.04.003_bib58","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.cmi.2018.01.010","article-title":"Efficacy and safety of fosfomycin plus imipenem versus vancomycin for complicated bacteraemia and endocarditis due to methicillin-resistant Staphylococcus aureus: a randomized clinical trial","volume":"24","author":"Pericas","year":"2018","journal-title":"ClinMicrobiol Infect"},{"issue":"1","key":"10.1016\/j.idc.2020.04.003_bib59","first-page":"34","article-title":"Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin","volume":"15","author":"Kocsis","year":"2016","journal-title":"Ann ClinMicrobiolAntimicrob"},{"issue":"Supplement_3","key":"10.1016\/j.idc.2020.04.003_bib60","doi-asserted-by":"crossref","first-page":"S223","DOI":"10.1093\/cid\/ciz006","article-title":"Analysis of pooled phase III efficacy data for delafloxacin in acute bacterial skin and skin structure infections","volume":"68","author":"Giordano","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2020.04.003_bib61","series-title":"Baxdela [package insert]","year":"2019"},{"issue":"8","key":"10.1016\/j.idc.2020.04.003_bib62","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/cid\/ciz787","article-title":"Emergence of Delafloxacin-Resistant Staphylococcus aureus in Brooklyn, NY","volume":"70","author":"Iregui","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552020300192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552020300192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:19:04Z","timestamp":1760195944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552020300192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0891552020300192"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2020.04.003","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bacteremia due to Methicillin-Resistant Staphylococcus aureus","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2020.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}